Respiratory Syncytial Virus (RSV) as a Secondary Diagnosis among Hospitalized Patients in Germany: Outcomes and Economic Burden
Our study provides a deeper understanding of how RSV secondary diagnosis affects hospitalized patients, finding that RSV infection dramatically increases mortality rate, LOS, and inpatient healthcare costs. These findings support a broad RSV-vaccination recommendation for this patient group.
Authors
- M. Weinert (ORCID: https://orcid.org/0009-0003-5641-6881)
- Kristina Dobrindt (ORCID: https://orcid.org/0000-0002-6585-8513)
- Jens Gottlieb (ORCID: https://orcid.org/0000-0002-9540-9022)
- B. Ultsch (ORCID: https://orcid.org/0000-0001-6685-2992)
- Manuel Batram (ORCID: https://orcid.org/0000-0003-4445-965X)
- Jana Diekmannshemke
- Darshan H. Mehta (ORCID: https://orcid.org/0000-0003-0457-4717)
- Kendra M. Braegelmann
- Julian Witte (ORCID: https://orcid.org/0000-0003-2075-323X)
- Stefan Scholz (ORCID: https://orcid.org/0000-0002-8421-8829)
Institutions
- Medizinische Hochschule Hannover (DE)
- Moderna Therapeutics (United States) (US)
- KHD Humboldt Wedag (Germany) (DE)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1007/s40121-025-01152-z
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Moderna